Tag Archives: NASDAQ:ATRS

H.C. Wainwright Reiterates Their Buy Rating on Antares Pharma (ATRS)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Antares Pharma (ATRS – Research Report), with a price target of $4.50. The company’s shares closed on Friday at $3.04. Livnat said: “We’re encouraged to

Antares Pharma (ATRS) Received its Third Buy in a Row

After Jefferies and Raymond James gave Antares Pharma (NASDAQ: ATRS) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Oren Livnat maintained a Buy rating on Antares Pharma today and set a price

H.C. Wainwright Believes Antares Pharma (NASDAQ: ATRS) Won’t Stop Here

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (ATRS – Research Report) today and set a price target of $4.50. The company’s shares closed yesterday at $3.61, close to its 52-week high of $3.93. Livnat said:

Antares Pharma (ATRS) Gets a Buy Rating from Piper Jaffray

In a report issued on August 16, David Amsellem from Piper Jaffray reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS), with a price target of $4. The company’s shares closed yesterday at $3.39. According to TipRanks.com, Amsellem is a

A Director at Antares Pharma is Exercising Options

Today, a Director at Antares Pharma, Leonard Jacob, exercised options of Antares Pharma for $27.55K. The options were close to expired and Leonard Jacob retained stocks. Following this transaction Leonard Jacob’s holding in the company was increased by 15.62% to

Analysts Offer Insights on Healthcare Companies: Antares Pharma (NASDAQ: ATRS) and Galmed Pharmaceuticals (NASDAQ: GLMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (NASDAQ: ATRS) and Galmed Pharmaceuticals (NASDAQ: GLMD) with bullish sentiments. Antares Pharma (NASDAQ: ATRS) In a report released today, Oren